3-V Biosciences raises $20m for solid tumor study
This article was originally published in Scrip
Executive Summary
Menlo Park, California-based 3-V Biosciences raised $20 million in a Series C venture funding round, which will finance a Phase I clinical trial for the company's lead oncology drug candidate.